96 related articles for article (PubMed ID: 19796689)
21. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen.
Wigelsworth DJ; Krantz BA; Christensen KA; Lacy DB; Juris SJ; Collier RJ
J Biol Chem; 2004 May; 279(22):23349-56. PubMed ID: 15044490
[TBL] [Abstract][Full Text] [Related]
22. Anthrax toxin receptor 2 mediates Bacillus anthracis killing of macrophages following spore challenge.
Banks DJ; Barnajian M; Maldonado-Arocho FJ; Sanchez AM; Bradley KA
Cell Microbiol; 2005 Aug; 7(8):1173-85. PubMed ID: 16008584
[TBL] [Abstract][Full Text] [Related]
23. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection.
Hepler RW; Kelly R; McNeely TB; Fan H; Losada MC; George HA; Woods A; Cope LD; Bansal A; Cook JC; Zang G; Cohen SL; Wei X; Keller PM; Leffel E; Joyce JG; Pitt L; Schultz LD; Jansen KU; Kurtz M
Vaccine; 2006 Mar; 24(10):1501-14. PubMed ID: 16271808
[TBL] [Abstract][Full Text] [Related]
24. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.
Maynard JA; Maassen CB; Leppla SH; Brasky K; Patterson JL; Iverson BL; Georgiou G
Nat Biotechnol; 2002 Jun; 20(6):597-601. PubMed ID: 12042864
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of a subunit vaccine against Bacillus anthracis.
Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
[TBL] [Abstract][Full Text] [Related]
26. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
[TBL] [Abstract][Full Text] [Related]
27. Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta.
Brodzik R; Bandurska K; Deka D; Golovkin M; Koprowski H
Biochem Biophys Res Commun; 2005 Dec; 338(2):717-22. PubMed ID: 16236249
[TBL] [Abstract][Full Text] [Related]
28. Activity of the Bacillus anthracis 20 kDa protective antigen component.
Hammamieh R; Ribot WJ; Abshire TG; Jett M; Ezzell J
BMC Infect Dis; 2008 Sep; 8():124. PubMed ID: 18808698
[TBL] [Abstract][Full Text] [Related]
29. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo.
Liu S; Crown D; Miller-Randolph S; Moayeri M; Wang H; Hu H; Morley T; Leppla SH
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12424-9. PubMed ID: 19617532
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor.
Lacy DB; Wigelsworth DJ; Scobie HM; Young JA; Collier RJ
Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6367-72. PubMed ID: 15079089
[TBL] [Abstract][Full Text] [Related]
31. Expression and purification of functional human anthrax toxin receptor (ATR/TEM8) binding domain from Escherichia coli.
Ding Z; Bradley KA; Amin Arnaout M; Xiong JP
Protein Expr Purif; 2006 Sep; 49(1):121-8. PubMed ID: 16798009
[TBL] [Abstract][Full Text] [Related]
32. Past, imminent and future human medical countermeasures for anthrax.
Baillie LW
J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809
[TBL] [Abstract][Full Text] [Related]
33. A soluble receptor decoy protects rats against anthrax lethal toxin challenge.
Scobie HM; Thomas D; Marlett JM; Destito G; Wigelsworth DJ; Collier RJ; Young JA; Manchester M
J Infect Dis; 2005 Sep; 192(6):1047-51. PubMed ID: 16107958
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of a complex between anthrax toxin and its host cell receptor.
Santelli E; Bankston LA; Leppla SH; Liddington RC
Nature; 2004 Aug; 430(7002):905-8. PubMed ID: 15243628
[TBL] [Abstract][Full Text] [Related]
35. Quantitative measurement of anthrax toxin receptor messenger RNA in primary mononuclear phagocytes.
Premanandan C; Lairmore MD; Fernandez S; Phipps AJ
Microb Pathog; 2006; 41(4-5):193-8. PubMed ID: 16854559
[TBL] [Abstract][Full Text] [Related]
36. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
37. Expression of soluble recombinant TGF-beta type II receptor fused with the Fc portion of human IgG1 (sTbetaRII-Fc) in NS0 cells.
Kwiatkowska EP; Kazimierczak U; Mackiewicz A; Kowalczyk DW
Acta Biochim Pol; 2006; 53(2):361-9. PubMed ID: 16733563
[TBL] [Abstract][Full Text] [Related]
38. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components.
Hahn UK; Boehm R; Beyer W
Vaccine; 2006 May; 24(21):4569-71. PubMed ID: 16157424
[TBL] [Abstract][Full Text] [Related]
39. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
Huang C
Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
[TBL] [Abstract][Full Text] [Related]
40. [Eukaryotic expression of human LIGHT-Fc chimeric molecule and its anti-tumor activity].
Huang G; Bai Y; Jiang M; Li WL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Sep; 19(5):499-502. PubMed ID: 15169669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
